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Abstract: Rheumatic fever (RF) is a sequel of group A streptococcal throat infection and 
occurs in untreated susceptible children. Rheumatic heart disease (RHD), the major sequel of 
RF, occurs in 30%–45% of RF patients. RF is still considered endemic in some regions of Brazil 
and is responsible for approximately 90% of early childhood valvular surgery in the country. 
In this study, we present a 15-year clinical follow-up of 25 children who underwent surgical 
valvular repair. Histopathological and immunological features of heart tissue lesions of RHD 
patients were also evaluated. The patients presented severe forms of RHD with congestive 
symptoms at a very young age. Many of them had surgery at the acute phase of RF. Histological 
analysis showed the presence of dense valvular inﬂ  ammatory inﬁ  ltrates and Aschoff nodules 
in the myocardium of 21% of acute RHD patients. Inﬁ  ltrating T-cells were mainly CD4+ in 
heart tissue biopsies of patients with rheumatic activity. In addition, CD4+ and CD8+ inﬁ  ltrating 
T-cell clones recognized streptococcal M peptides and cardiac tissue proteins. These ﬁ  ndings 
may open the possibilities of new ways of immunotherapy. In addition, we demonstrated that 
the surgical procedure during acute phase of the disease improved the quality of life of young 
RHD patients.
Keywords: rheumatic heart disease, Streptococcus pyogenes, heart failure, inﬂ  ammatory 
inﬁ  ltrate, T lymphocytes, molecular mimicry
Introduction
Rheumatic fever (RF), a sequel of group A streptococcal throat infection occurs in 
untreated susceptible children and is a multisystem inﬂ  ammatory disease. The clini-
cal signs of RF are the same throughout the world. In the 1950s, Jones established 
the major criteria for diagnosing initial attacks of RF, which comprised polyarthritis, 
carditis, and chorea. These criteria were revised in 1965 and the second and latest 
revision done in 1992 remains useful to date (Dajani et al 1992). Arthritis is the earliest 
and most common feature of the disease, present in 60%–80% of patients. Carditis, 
the most serious manifestation of the disease, occurs a few weeks after Streptococcus 
pyogenes throat infection in 30%–45% of RF patients, and usually presents as pancar-
ditis. Endocarditis is the most serious sequel and frequently leads to chronic rheumatic 
heart disease (RHD). Valvular lesions and mitral and aortic regurgitation are the most 
common events caused by repeated valvulitis.
RHD remains a major public health problem in developing countries, leading to 
233,000 deaths/year (Carapetis, McDonald et al 2005; Carapetis, Steer et al 2005). The 
incidence of RHD in the world is at least 15.6 million cases and the highest documented 
prevalence of the disease among children from developing countries is 5.7 per 1,000 
in sub-Saharan Africa (Carapetis, McDonald et al 2005; Carapetis, Steer et al 2005). 
Epidemiological data from many developing countries are still of poor quality, and the 
numbers of RHD cases are surely higher than those known. In Brazil, the incidence 
of acute RF has decreased by 75% in the last 10 years however acute RF is still high, 
reaching 5000 new cases in 2002 (data from the Brazilian Health Ministry).Vascular Health and Risk Management 2007:3(6) 1008
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The pathogenesis of RHD depends on several host factors 
that mediate a pathological autoimmune response triggered 
by a defensive immune response against S. pyogenes. Genetic 
predisposition is one of the leading factors contributing to 
the development of autoimmunity.
The association of certain HLA class II alleles with 
autoimmune diseases is frequent due to the fact that these 
molecules are expressed on the surface of antigen-present-
ing cells (APC) such as macrophages, dendritic cells, and 
B lymphocytes, which present pathogen antigens and trigger 
the activation of T and B cells.
Several HLA class II alleles have been associated with 
the development of RF/RHD in different countries (reviewed 
by Guilherme et al 2005). Among these alleles, HLA-DR7 is 
the most frequently associated with RF/RHD and seems to 
be related to the development of multiple valvular lesions. 
The TNFA gene related to inﬂ  ammatory responses is located 
near HLA class II genes and has been associated with 
several autoimmune diseases. The presence of either one of 
the TNFA alleles (-308A and -238A) was associated with 
the development of RF and RHD (Hernandez-Pacheco et al 
2003). We also observed the same association with patients 
that develop aortic valve lesions (Ramasawmy et al 2006).
Severe RHD is mediated mainly by T lymphocytes, which 
participate in a delayed-type hypersensitivity reaction lead-
ing to local inﬂ  ammation. We have shown the signiﬁ  cance 
of molecular mimicry between beta hemolytic streptococci 
and heart tissue proteins through an analysis of the T-cell 
repertoire leading to local tissue damage in RHD. We have 
also demonstrated the ability of T-cell clones inﬁ  ltrating the 
heart lesions of severe RHD patients to recognize M protein 
peptides and heart tissue-derived proteins (Guilherme et al 
1995).
In this work, we presented a cohort of 25 young RHD 
patients that had been submitted to a surgery during an acute 
RF episode, an unusual procedure and we showed that they 
had a good prognosis. We also evaluated the histopathologi-
cal and immunological features of this group of patients in 
order to verify the presence of inﬂ  ammatory reactions in 
the heart tissue.
Patients and methods
We studied 25 severe RHD patients, 17 males and 8 females 
who underwent cardiac valvular surgery before 16 years 
of age, in which 14 (56%) presented an acute RF episode. 
The other 11 patients also have had recent acute RF epi-
sode. The patients were followed from 1990 to 2006 at the 
Heart Institute, University of São Paulo. Their age at the 
ﬁ  rst clinical evaluation varied from 6 to 16 years (mean = 
10.6 ± 2.6 years). The initial attack of RF had occurred from 
3 to 16 years of age (mean = 9.5 ± 3.4 years) and was clini-
cally deﬁ  ned by the presence of polyarthritis in 13 patients, 
carditis in 24 patients, and fever in one patient. Only one 
patient studied presented with Sydenham chorea during 
the clinical evolution of the disease. For immunological 
and histopathological evaluations, heart tissue fragments 
were collected during valve surgery. Fragment collection 
was approved by the Heart Institute Ethics Committee 
(HC-FMUSP) and informed consent was obtained from the 
parents of the patients participating in the study.
Histological analysis
and immunohistochemistry
Histological sections from heart fragments obtained during 
valve surgery in twenty-four patients were stained with hema-
toxylin-eosin (HE) and were reviewed by two pathologists, 
in order to evaluate histological features of acute and chronic 
RHD, such as inﬂ  ammatory inﬁ  ltrates, rheumatic activity, 
neovascularization, ﬁ  brosis, and calciﬁ  cation.
Heart fragments included valvular tissue from aortic 
(AV; n = 7 patients) and mitral (MV; n = 7 patients) valves, 
myocardial tissue from the right atrium (RA; n = 5 patients), 
left atrium (LA; n = 18 patients) and papillary muscles (PM; 
n = 2 patients), and pericardium (PER; n = 5 patients).
Anti-CD4 (MT 310) and anti-CD8 (DK 25) (Dakopatts) 
monoclonal antibodies were used to deﬁ  ne T-cell subpopula-
tions and anti-CD20 (L26) (Dakopatts) for B cell populations. 
Peroxidase-coupled avidin (Dakopatts) was added later and 
the reaction was developed with diamino-benzidine (Sigma-
Aldrich).
Establishment of heart inﬁ  ltrating T-cell 
lines and T-cell clones
Heart inﬁ  ltrating T-cell lines (HIL) were established from 
surgical fragments as described before (Guilherme et al 
1995). Brieﬂ  y, heart tissue was ﬁ  nely minced, placed in 
ﬂ  at-bottom 96-well plates (Becton and Dickson, Lincoln 
Park, NJ) with Dulbecco’s modiﬁ  ed Eagle medium (DMEM) 
(Invitrogen, Life Technologies) supplemented with 2 mM 
L-glutamine (Invitrogen), 10% pooled normal human serum, 
antibiotics (Gentamycin 40 μg/ml and Peﬂ  acyn 20 μg/ml), 
and 40 IU/ml of human recombinant IL-2 (PeproTech Inc) 
on a HLA-DR-matched feeder layer of peripheral blood 
mononuclear cells (PBMC, 105 cells/well), irradiated at 5000 
rad. All T-cell lines were further expanded with irradiated 
HLA-DR matched feeder cells and Phytohemagglutinin Vascular Health and Risk Management 2007:3(6) 1009
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(PHA-P, 2.5 μg/ml). T-cell clones were obtained by the 
limiting dilution method in the presence of 105 HLA-DR 
matched PBMC, irradiated PHA-P (2.5 μg/ml), and IL-2 
(20 IU/ml). For T-cell clones expansion, we also used IL-7 
and IL-15 (2.5 ng/ml, PeproTech Inc).
Peptide synthesis
Streptococcal M5-derived peptides were synthesized by 
the “tea bag” method using t-BOC chemistry (Houghten 
et al 1985), checked by mass spectrometry, and puri-
ﬁ  ed by high pressure liquid chromatography (HPLC). 
Fifty peptides of the light meromyosin (LMM) fragment 
provided by Dr. M.W. Cunningham were designed based 
on the cardiac myosin β-chain protein sequence (Diederich 
et al 1989) and were synthesized as 18-mer peptides with 
a 5-amino acid overlap as previously described (Galvin 
et al 2002). Twenty-two N-terminal overlapping M5 
peptides were synthesized as 15- to 20-mers, based on the 
streptococcal M5 protein sequence (Phillips et al 1981; 
Manjula et al 1985). See Table 5 for sequences of peptides 
recognized by T-cells in a proliferation assay.
Preparation of heart tissue proteins
Heart tissue fractions were obtained from lysates of postmor-
tem normal human myocardium and aortic valve tissue, and 
then separated by SDS-PAGE (1D-electrophoresis). Mitral 
valve-derived proteins were separated by 2D-electrophoresis 
that combined urea isoelectrofocusing electrophoresis 
(IEF) using a broad range carrier ampholytes mixture 
(pH = 3.6−9.2) in the ﬁ  rst dimension, with SDS-PAGE 
(5%−15% polyacrylamide gel) electrophoresis in the sec-
ond dimension in order to resolve valvular tissue proteins 
by isoelectric point and molecular weight as previously 
described (O’Farell et al 1975). All proteins isolated by both 
1D- and 2D-electrophoresis were blotted onto nitrocellulose 
membranes (Abou-Zeid et al 1987). The blots were divided 
into several horizontal strips with approximately the same 
amount of protein. A nitrocellulose strip without protein 
was used as negative control. The strips were solubilized 
in dimethyl sulfoxide (E. Merck), reprecipitated in sodium 
carbonate/sodium bicarbonate buffer 0.05 mol/L, pH 9.6, 
and washed with RPMI 1640 medium (Sigma), yielding a 
ﬁ  ne suspension of protein-loaded nitrocellulose particles that 
were used as antigens for the proliferation assay.
Proliferation assay
Proliferation assays were performed in 96-well plates 
incubating 3 × 104 T-cell clones with 105 irradiated (5000 rad) 
HLA-DR matched mononuclear cells or 105 peripheral blood 
mononuclear cells (PBMC) with 5 μg/ml of streptococcal 
M5 synthetic peptides, 3 μM of light meromyosin peptides 
(LMM), and 50 μl/well of heart tissue proteins for 96h at 
37  C in a humidiﬁ  ed 5% CO2 incubator. Negative controls 
were a suspension of lymphoblasts and irradiated PBMC in 
DMEM for the peptides and 50 μl of a protein-free nitrocel-
lulose suspension for valve protein experiments. PHA-P 
(2.5 μg/ml) was used as the positive control for proliferative 
responses. All antigens were tested in triplicate and pulsed-
labeled with 0.5 μCi/well of tritiated thymidine (Amersham) 
for the ﬁ  nal 18h of culture. Cells were then harvested and 
analyzed in an automated beta counter (Beta plate 1205-
LKB). A proliferative response was considered positive 
when the stimulation index (SI) was  2.5. Negative controls 
presented less than 500 cpm.
Statistical analysis
The statistical analysis was accomplished with software SAS 
and GraphPad Prism v. 4.00 and a p value   0.05 was consid-
ered statistically signiﬁ  cant. Means and standard deviations 
were calculated for quantitative variables. Paired and unpaired 
Student’s t-Test were used when appropriated. Kaplan-Meyer 
was applied for survival analysis. The Mann-Whitney test 
was employed to evaluate the relation between the numbers 
of inﬁ  ltrating T lymphocytes and rheumatic activity.
Results
All patients (100%) had mitral valve disease. Isolated mitral 
disease was observed in 9 patients, and mitral combined with 
aortic valve disease in 8 patients. Mitral and tricuspid valve 
was seen in one patient and trivalvular valve disease (aortic, 
mitral, and tricuspid) in 7 patients (Table 1). Tricuspid valve 
regurgitation secondary to mitral valve disease and pulmo-
nary hypertension was seen in 16 patients.
At the time of the ﬁ  rst surgery, the majority of patients 
had advanced heart failure due to severe valvular disease. 
Two patients presented in New York Heart Association 
(NYAH) functional class II, 7 in class III, and 16 in class 
IV (Table 1).
Ten patients underwent heart surgery during an episode of 
acute rheumatic carditis associated with severe heart failure. 
Moreover, 4 patients who underwent valve surgery soon after 
had been treated for acute carditis. Of those, 2 had recurrence 
of acute carditis after surgery, resulting in worsening of valve 
and myocardium disease.
Isolated mitral disease or disease associated with another 
valvular dysfunction was the main cause of heart failure Vascular Health and Risk Management 2007:3(6) 1010
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leading to heart surgery in 22 out of 25 patients (88%). Three 
patients (#1, 5 and 19) (mean age = 14.3 ± 0.6) underwent 
surgery due to mitral stenosis. Among the 22 patients with 
mitral valve dysfunction, isolated mitral valve regurgitation 
occurred in 3 patients, mitral regurgitation combined with tri-
cuspid regurgitation in 3, combined with aortic regurgitation 
in 4, and associated with aortic and tricuspid valve in 12.
The mean age at the time of ﬁ  rst surgery was 12.0 ± 2.8 
years. Eighteen patients underwent conservative mitral valve 
surgery (15 repairs and 3 commissurotomies). There were 
4 repairs of the tricuspid valve and 7 of the aortic valve. 
Additionaly, there were 12 implants of biological prostheses 
(6 mitral and 6 aortic), and one patient received two mechani-
cal prostheses (in aortic and mitral positions).
After surgery, we noticed a reduction of left ventricle 
diastolic and left atrium diameters (Table 2). In addition, 
the left ventricular shortening fraction had a mild reduction 
(Table 2).
During follow-up, 7 (28%) patients underwent reopera-
tions. Bioprosthesis stenosis was the main cause of reopera-
tion, occurring in 4 cases. Anterior chordal rupture and acute 
mitral valve regurgitation occurred in one patient. Mitral valve 
infective endocarditis and heart failure occurred in 2 cases.
Three patients died during long-term follow-up, all 
of them with a bioprosthesis. One patient had infective 
endocarditis two years after heart surgery. Another patient 
had bioprosthesis stenosis with severe heart failure and 
died due to cardiogenic shock after surgery. The last patient 
died one year after the second valvular surgery, also due to 
cardiogenic shock. The remaining patients had good clini-
cal evolution and are in NYHA class I or II (Figures 1 A 
and 1B).
Heart biopsies were retrieved from all patients except one 
(#22). Histopathologic data from valvular and myocardial 
tissues are summarized in Table 3. Both myocardium and 
valve samples were analyzed in nine patients (#1, 2, 3, 4, 6, 
9, 11, 12, 13). Only valvular or myocardium fragments were 
obtained from 3 (#8, 10, and 14) and 12 patients (#5, 7, 15, 
16, 17, 18, 19, 20, 21, 23, 24, 25), respectively. Inﬂ  ammatory 
reactions were observed in valvular tissues from 12 patients, 
varying from severe to mild intensity (Table 3), and in 10 
out of 12 myocardium fragments analyzed, mainly with mild 
intensity (Table 3). Rheumatic activity was conﬁ  rmed by 
the presence of ﬁ  brin deposits (verrucae) or Aschoff bodies 
(AB) in valvular tissue (#2, 3, 8, 10, and 11), myocardium 
(#2, 3, 11, 18, and 20), or pericardium (#12, 15 and 23, data 
not shown). Valvular neovascularization and ﬁ  brosis were 
observed in 10 and 11 patients, respectively, and graded 
according to intensity as mild, moderate, or severe. Calci-
ﬁ  cation was observed in only one valvular tissue analyzed 
(#1) (Table 3).
Visceral and both visceral and parietal pericardium from 
patients #15 and #12, 21, 23, 24, respectively, presented 
moderate ﬁ  brosis (data not shown). Pericardial inﬂ  amma-
tion was observed in 4 patients (#12, 15, 21 and 23), three 
of them with ﬁ  brin deposits in the connective tissue (#12, 
15, 23) (data not shown).
Immunohistochemical staining of heart tissue fragments 
(9 from valvular tissue and 14 from myocardium) of 18 pa-
tients showed the predominance of inﬁ  ltrating CD4+ T-cells 
(Table 4), except for two patients, one that we could not 
identify inﬁ  ltrating T-cells (#19) and the other that exhibited 
only a few CD8+ T-cells (#25) (Table 4).
Patients (#2, 3, 8, 10, 11, and 20) which presented histo-
logical features of rheumatic activity, showed an increased 
Table 1 Clinical data of RHD patients
Number of cases  25
Gender  Male: 17
  Female: 8
Mean age at the ﬁ  rst   9.5 ± 3.4
 episode  of  rheumatic 
 fever  (years) 
Valve damaged  Mitral: (25) – 100%
  Mitral isolated: (9) – 36%
  Mitral + aortic: (8) – 32%
  Mitral + tricuspid: (1) – 4%
  Trivalvular: (7) – 28%
Functional class (NYHA)  II – (2) – 8%
  III – (7) – 28%
  IV – (16) – 64%
( ): number of cases. 
Table 2 Echocardiography data before surgery and until seven days post surgical treatment
  Before surgery  Post - surgery  P
LVDD (mm)  63.60 ± 10.9  53.80 ± 11.1  0.003
LVSD (mm)  41.61 ± 8.8  37.50 ± 11  0.179
LAD (mm)  51.30 ± 12.0  41.62 ± 7.3  0.002
Shortening fraction (%)  34.32 ± 4.6  29.61 ± 7.2  0.009
Abbreviations: LVDD, left ventricle diastolic diameter; LVSD, left ventricle systolic diameter; LAD, left atrium diameter.Vascular Health and Risk Management 2007:3(6) 1011
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number of heart tissue inﬁ  ltrating CD4+ (mean = 3.7± 2.9 cells, 
p = 0.03) and CD8+ T-cells (mean = 1.4 ± 1.2 cells, p = 0.03) when 
compared with patients without rheumatic activity (Figure 2). 
In addition, we observed a higher number of CD4+ T-cells than 
CD8+ T-cells in the group with rheumatic activity.
We established T-cell lines from heart tissue fragments 
(valves and/or myocardium) from 18 out 25 of patients that 
allowed us to obtain 72% of inﬁ  ltrating T-cells growing 
(Figure 3). Among the T-cell lines established, we also ob-
served a predominance of CD4+ T-cells (data not shown).
Intralesional T-cell clones from the valves and myocar-
dium were established from T-cell lines of 7 patients (#1, 
3, 4, 5, 7, 8, and 10). Table 5 shows the reactivity of heart 
tissue-derived T-cell clones from each patient. Several heart 
tissue proteins from myocardium and/or valvular tissue and 
streptoccal M5 synthetic peptides were recognized by these 
T-cell clones as well as some cardiac myosin synthetic pep-
tides (Table 5). Five T-cell clones (3.1.79, 4.1.18, 5.1.31, 
7.1.1, and 8.1.2) were CD4+ and T-cell clones 1.1.27 and 
10.2.13 were CD8+.
Peripheral blood reactivity against M5 peptides and car-
diac proteins were analyzed for 12 patients (#2, 3, 4, 5, 7, 9, 
11, 13, 15, 17, 19, and 20) at the time of the surgery. Eight 
patients (#3, 4, 5, 11, 13, 15, 17, and 19) presented T-cells in 
the periphery able to recognize M5 peptides and/or cardiac 
proteins (Table 6). The M5 peptides and cardiac proteins 
recognized by peripheral T-cells were the same recognized 
by intralesional T-cell clones (Table 5).
Discussion
Rheumatic fever is still considered endemic in some regions 
of Brazil and RHD is responsible for approximately 90% 
of early childhood valvular surgeries in the country. In this 
study, we present a 15-year follow-up of 25 children that 
underwent valvular surgery repair.
We describe a group of rheumatic heart disease patients 
that have developed congestive symptoms at a very young 
age, a particularly severe form of the disease. Most patients 
with RHD do not develop congestive symptoms until adult-
hood. The severity of the disease of these young patients is 
related to recurrent outbreaks of acute rheumatic fever or a 
particularly severe ﬁ  rst attack of rheumatic fever (Velloso 
et al 1991; Tarasoutchi et al 2005).
Surgery after a single attack of rheumatic fever is related 
to very intense valve damage, usually with ruptured mitral 
valve chordae due to acute valvulitis (Hillman et al 2004). 
Many of our patients had surgery during or soon after an 
acute phase of rheumatic fever. These patients usually 
presented myocarditis at the time of the surgery, leading to 
a turbulent post-operatory period because of myocarditis-
induced ventricular dysfunction. Even so, we could not 
relate surgery in the acute phase of rheumatic fever with an 
increased possibility of reoperation (p = 0.362) or excess 
of mortality. It is possible that these patients have a larger 
number of cross-reactive lymphocyte clones or that these 
clones may be more active in inducing inﬂ  ammation and 
damage (Guilherme et al 1995).
The remaining patients were submitted to surgery in 
the chronic phase of RHD. This population differs from 
the patients operated in the acute phase because they usually 
have severe valve damage secondary to repeated bouts 
of acute rheumatic fever. This population more closely 
resembles the adult population with rheumatic valve disease, 
usually having mild symptomatic or asymptomatic acute 
carditis, but severe sequelae due to chronic RHD. The lack 
of acute symptoms in this population leads to a delayed 
diagnosis of rheumatic fever, and thus delayed access to 
secondary prophylaxis and medical care (Rizvi et al 2004). 
The ﬁ  rst symptoms that lead the patient to seek medical care 
are usually heart failure, not necessarily related to the acute 
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Figure 1 Kaplan-Meier survival curve: follow-up of 25 rheumatic valve disease 
patients. (A) Event-free survival (death and reoperation); (B) probability of survival.Vascular Health and Risk Management 2007:3(6) 1012
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phase of rheumatic fever. In both acute and chronic patients, 
we observed that histopathological and immunological 
analysis presented similar numbers of cross-reactive T-cells. 
However, the group that had surgery in the acute phase of the 
disease probably exhibited a large number of cross-reactive 
lymphocytes secondary to a single throat infection while 
patients in the chronic phase of the disease exhibited small 
numbers of cross-reactive lymphocytes that emerged from 
repeated streptococcal throat infections (Guilherme et al 
2001).
Many of our patients needed cardiac surgery immediately 
after the ﬁ  rst attack of rheumatic fever due to the severity of 
this ﬁ  rst episode. In these cases the prevention strategy using 
primary prophylaxis could be effective. Secondary prophy-
laxis could prevent the development of lesions due to a new 
acute rheumatic fever episode. There are a consensus among 
physicians that secondary prophylaxis for rheumatic fever is 
more cost-effective to prevent new RF episodes (Carapetis, 
Steer et al 2005; Carapetis et al 2006).
Histological evaluation of the heart valves in 24 RHD 
patients were completed and provided evidence about the 
severity of involvement as well as the phase of the disease. 
Features like ﬁ  brosis and neovascularization were observed 
in most of valves analyzed, indicating that the valve has gone 
through previous episodes of rheumatic activity. Usually, 
the degree of ﬁ  brosis is also proportional to the number of 
acute episodes. Calciﬁ  cation, a feature that points to chronic 
valvular involvement, was observed in only one patient. In-
ﬂ  ammatory inﬁ  ltrates may be sparse and patchy in the chronic 
lesions, but are usually dense in the acute phase of the disease. 
The concomitant presence of ﬁ  brin deposits (verrucae) on the 
endocardial surface implies that there is rheumatic activity. 
In our patients we observed dense valvular inﬂ  ammatory 
inﬁ  ltrates characterized mainly as CD4+ T-cells.
Table 4 Evaluation of heart-tissue inﬁ  ltrating lymphocytes 
subsets
Patients  Heart   B cell *  T -cells*    CD4/CD8
#  tissue  cells / HPF  Cells/ HPF 
     CD4+    CD8+ 
2 MV  2.2  1.6  0.6  2.7
3 PM  ND  9.4  3.3  2.8
 MV  0  3.2 2.4  1.3
4 LA  ND  6.1  1.2  5.0
6 AV  0.3  0.9  0.5  1.8
7 LA  0.2  4.5  0.9  5.0
 MV  0.2 1.2 1.2  1.0
8 LA  0.01 1.4  0.5  2.8
 MV  0  3.5 0  a
9 MV  0.02 0.2  0  a
 PM  0.1 1.0 0  a
10 MV  1.5  2.4  1.7  1.4
11 MV  1.4  2.5  0.8  3.1
 PM  0.3 0.3 0.2  1.5
12 LA  0.1  0.1  0.03  3.3
13 LA  0  0.3    0.3  1.0
15 LA  2.4  3.1  0.1  31.0
17 LA  0.3  0.7  0.3  2.3
19 LA  0  0  0  0
20 LA  0.3  2.6  2.0  1.3
22 LA  ND  0.9  0.5  1.8
23 MV  2.7  1.5  0.4  3.7
25 LA  0  0  0.3  b
Notes: *Immunohistochemistry.
Abbreviations: HPF, high power microscopical ﬁ  eld; LA, left atrium; MV, mitral valve; AV, 
aortic valve; PM, papillary muscle; ND, not done; a, only CD4+ T-cells; b, only CD8+ T-cells. 
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Figure 2 The presence of heart tissue T lymphocytes is related with rheumatic activity. The number of inﬁ  ltrating T and B lymphocytes and their relation with rheumatic 
activity in both valve and myocardium tissues are presented. Black bars, mean tissue with rheumatic activity and white bars, without rheumatic activity. *P = 0.03; **P = 0.03. 
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On the other hand, the analysis of myocardial biopsies 
may not bring signiﬁ  cant contribution to the diagnosis of 
RHD, since the ﬁ  nding of Aschoff nodules is rare: present 
in 30% of acute RHD biopsies and in 40% of patients with 
recurrent RF attacks (Narula et al 1993). We observed 
Aschoff nodules in 21% of the acute RHD patients studied. 
Although interstitial inﬂ  ammatory mononuclear cells may 
be present, myocardial cell damage, the main criterion 
for other types of myocarditis, is not a striking feature in 
RHD. However, there is strong evidence that the nature of 
myocardial inﬁ  ltrating cells is different from those present 
in valvular lesions (Guilherme et al 2004). We showed 
that mononuclear cells from heart lesions predominantly 
secrete IFNγ and TNFα, Th1-type cytokines, in both acute 
RF and chronic RHD patients. Previous results from our 
group showed sparse production of IL-4 by valve-inﬁ  ltrating 
Figure 3 Heart inﬁ  ltrating T-cells. Heart tissue biopsies were cut in small fragments and kept in culture until establishment of T-cell lines. The picture represents 
lymphoblasts cultivated for 15 days in Dulbecco’s modiﬁ  ed Eagle medium supplemented with IL-2. Photograph from Immunology Laboratory, Heart Institute; original 
magniﬁ  cation x200.
Table 5 Cross reactive intralesional T-cell clones from RHD patients
Patients  Cross   CD4  CD8  Antigen recognition
#  reactive      M5 protein peptides / Heart tissue derived proteins 
  T -cell clones      or Cardiac myosin (LMM) peptides 
1 1.1.27    +  M5(11–25) 
       Myocardium  protein:   150 kDa to 44 kDa
3 3.1.79  +    M5(111–130) 
        Mitral valve proteins: 54–53 kDa/pI 7.76; 52 kDa/pI 4.3 
        LMM 31(1686–1703); LMM 49 (1921–1937)
4  4.1.18  +    M5(81–103) and M5(163–177)
        Aortic valve proteins: 100–115–120 kDa; 43–46–50 kDa
5* 5.1.31 +    M5(62–82)
        Myocardium protein: 90–150 kDa
        Aortic valve protein: 43–65 kDa
7 7.1.1 +    M5(81–96);  M5(83–103)
       Myocardium  protein:   150 kDa
        Aortic valve proteins : 90–150 kDa; 43–65 kDa
8 8.1.2 +    M5(81–96)
        Myocardium protein: 95–150 kDa
10  10.2.13    +  Mitral valve proteins: 58; 37 kDa/pI 5.12
       LMM14(1400–1417);  LMM36(1751–1768); 
       LMM38(1777–1795);  LMM40(1803–1834)
Notes: T-cell clones were derived from mitral or aortic valve, except T-cell clone 5.1.31 (*) that was derived from left atrium (LA). Sequences of recognized peptides: 
M5 protein (Manjula et al, 1985; Phillips et al, 1981; Guilherme et al, 1995, 2000 and 2001): 11–25-QRAKEALDKYELENH; 62–82-LERKTAELTSEKKEHEAENDK; 81–96-
DKLKQQRDTLSTQKET; 83–103-LKQQRDTLSTQKETLEREVQN; 111–130-TRQELANKQQESKENEKALN; 163–177- ETIGTLKKILDETVK. Cardiac myosin (LMM-
light meromyosin) peptides (Diederich et al, 1989; Galvin et al, 2000; Fae et al, 2006): LMM14-(1400–1417) SQSELESSQKEARSLSTE; LMM31-(1686–1703) ELEELRAV-
VEQTERSRKL; LMM36-(1751–1768) RNAEEKAKKAITDAAMMA; LMM-38 (1777–1795) TSAHLERMKKNMEQTIKD; LMM40-(1803–1840) EQIALKGGKKQLQKLEAR; 
LMM 49-(1921–1937) LEARVRELENELEAEQKR.Vascular Health and Risk Management 2007:3(6) 1015
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cells (under 10% IL-4 positive cells) in 82% of the valve 
fragments analyzed and large numbers of IL-4 positive cells 
(over 50%) in 78% of the myocardium fragments analyzed. 
This suggests that low numbers of IL-4 producing cells in the 
valvular tissue may contribute to the progression of valvular 
RHD lesions. These observations suggest the involvement 
of different mononuclear cells in the myocardium and the 
valves. The fact that different types of cytokine producing 
cells were found reinforces the putative role of regulatory 
cytokines in myocardium healing in RHD and in the induc-
tion of progressive and permanent valve damage (Guilherme 
et al 2004).
The molecular mimicry mechanism mediating RF/RHD 
is the process in which T-and B lymphocytes recognize 
self-antigens showing some degree of homology with 
streptococcal antigens. Although several cross-reactive 
antibodies have been described (reviewed by Cunningham 
2000 and 2003), their potential role in the development of 
RHD has only recently been clariﬁ  ed. Studies conducted by 
Cunningham’s group describe cross-reactive antibodies able 
to bind to the endothelial surface, leading to inﬂ  ammation, 
cellular inﬁ  ltration, and valve scarring (Galvin et al 2000). The 
upregulation of the adhesion molecule VCAM-1 after binding 
of cross-reactive antibodies to the valvular endothelium 
facilitates cellular inﬁ  ltration (Roberts et al 2001). Our results 
showed that 91% of heart biopsies exhibited cellular inﬁ  ltra-
tion with a predominance of CD4+ T-cells, in agreement with 
previous results (Guilherme et al 1995). In addition, in the 
present study we observed the highest number of both CD4+ 
and CD8+ T-cells in patients that presented rheumatic activity. 
These results conﬁ  rmed previous date (Guilherme et al 2001) 
in which we analyzed the reactivity of intralesional T-cells of 
three RHD patients, one in acute phase, one six month after 
acute phase and, one in chronic phase of the disease. We 
observed the presence of 67% of auto reactive T-cell clones 
in the valve of patient in acute phase of the disease while the 
other two patients presented around 25%–30% of auto reactive 
T-cell clones (Guilherme et al 2001). The date presented here 
indicated that during acute episode there are expansions of 
auto reactive T-cells in the heart and after the acute episode 
these auto reactive T-cells decreased in numbers but it is still 
important to maintain the heart lesions.
Intralesional T-cell clones able to recognize streptococcal 
M peptides and heart tissue-derived proteins pointed out the 
Table 6 Peripheral blood reactivity against streptococcal M5 peptides and cardiac proteins
Patients M5(11−25) M5(62−82) M5(81−96) M5(83−103) M5(163−177) Cardiac  proteins  recognized
#      Stimulation index (SI) 
2 (−) (−) (−) (−) (−) Negative
3 8.6  13.4  5.4  4.8  15.0  Myocardium 
           12−24 kDa, SI − 3.6
4 7.7  (−) 4.8  (−) (−) Myocardium
            150 kDa, SI − 6.2
           Aortic  v
            150 kDa; 90−150 kDa, 65−90 kDa, 10−30 kDa
           SI  − 2.6; 3.6; 3.8; 2.4 and 6.2, respectively 
5 (−) (−) 2.6  (−) (−) Negative
7 (−) (−) (−) (−) (−) Negative
9 (−) (−) (−) (−) (−) Negative
11 2.8  3.2  4.0  4.5  3.8  Aortic  v 
           65−90 kDa, SI − 41.0
13 4.1  5.2  3.7  (−) (−) Negative
15 2.6  (−) (−) (−) 5.4  Aortic  v
           43−50 kDa, SI − 3.6
17 20.1  (−) (−) (−) (−) Mitral  v
           53  − 58, kDa/ pI 5.12, SI − 16.8 
           68− 56−52 kDa/5.94, SI−5.8
            \38 kDa/pI 4.23, SI −6.9
19 (−) (−) (−) (−) (−) Myocardium 
            150 kDa, SI − 2.4; 90−150 kDa, SI − 3.0; 
           10−30 kDa, SI − 2.4 Aortic v
           65−90 kDa, SI − 2.6 ; 30−45kDa, SI 2.5 
20 (−) (−) (−) (−) (−) Negative
Notes: Bold typed: positive reactions when stimulation index (SI)  2.5; (–) negative response; Sequences of peptides are represented in Table 5. Vascular Health and Risk Management 2007:3(6) 1016
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molecular mimicry mechanism that mediates the autoimmune 
reactions leading to valvular rheumatic lesions (Guilherme 
et al 1995; Faé et al 2006). The fact that some patients also 
exhibited T-cell reactivity in the periphery against strepto-
coccal M peptides and heart tissue-derived proteins gives 
support to the idea that streptococci-primed T-cells migrate 
from the periphery to the heart, triggering valvular lesions 
(Guilherme et al 2000; Faé et al 2004).
Taken together, our results show that although the major-
ity of patients had advanced heart failure due to severe valve 
disease and presented NYHA functional class (III/IV), they 
had different immunological patterns of responses against 
streptococcal and cardiac tissue proteins. These patterns 
could be illustrated by the immunological reactivity of 
patients 3 and 11 that exhibited rheumatic activity with a 
dense inﬂ  ammatory inﬁ  ltrate of CD4+ T-cells in the heart 
tissue. Both patients displayed a positive reactivity in the 
peripheral blood against M5 peptides and cardiac proteins. 
One of them (#3) also presented cross-reactive intralesional 
T-cell clones. On the other hand, patient 2 did not present 
reactivity in the periphery despite the presence of dense 
inﬂ  ammatory inﬁ  ltrates of CD4+ T-cells in the heart tissue, 
probably due to the low frequency of autoreactive T-cells 
in the periphery.
Our data illustrate that patients that underwent cardiac 
surgery mostly of them due to severe mitral regurgitation 
and severe heart failure during acute rheumatic fever episode 
were associated with a good late prognosis. Thus, when 
confronted with a patient with acute rheumatic carditis with 
expressive valvular dysfunction and refractory heart failure 
the clinician may consider surgery to treat the hemodynamical 
problem.
In conclusion, this work represents a well established, 
15-year follow-up of a child RHD cohort that underwent 
surgical treatment and demonstrated that the surgical proce-
dure during acute phase of the disease improved the quality 
of life of young RHD patients.
Most of the patients as mentioned before presented an 
inﬂ  ammatory reaction in the heart tissue and displayed 
peripheral and intralesional cross-reactive CD4+ T-cells 
against streptococcal M peptides and heart tissue proteins 
that may lead to the progression of the disease. In view to 
prevent this progression new ways of immunotherapy could 
be proposed. Young RHD patients could be beneﬁ  t by the use 
of the T-cell vaccination therapy (Cohen, I, 2001, reviewed) 
in which autologous primed T-cells could induce the deletion 
of pathological auto reactive T-cells and/or induce regula-
tory T-cells.
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